Generated by AI
Summary of Nov 16's posts. Generated by AI.
Summary of Jun 29's posts. Generated by AI.
Summary of Nov 16's posts. Generated by AI.
Investors talking about CYTK also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Cytokinetics, Incorporated is a specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing medicines that target muscle biology. Its current work centers on therapies for cardiac muscle dysfunction, particularly heart conditions in which the heart’s contractile performance is compromised. The company markets MYQORZO, an oral cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy, and is advancing additional drug candidates such as aficamten for broader hypertrophic cardiomyopathy use and omecamtiv mecarbil for heart failure. Cytokinetics also develops other muscle-directed candidates in clinical-stage programs, reflecting its emphasis on precision treatments for diseases affecting cardiac and skeletal muscle function. Headquartered in South San Francisco, California, Cytokinetics plays a specialized role in the biopharmaceutical market by focusing on muscle performance disorders within cardiovascular medicine.
Website350 Oyster Point Boulevard
South San Francisco, CA, 94080
United States
The latest articles about CYTK.